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“Sine doctrina, vita est quasi mortis imago” [Without, education,
life is but the image of death] Dionysius Cato (Roman author, Fl.
4th c. AD).
“If I can stop one heart from breaking, I shall not live in vain”
Emily Dickinson (American poet, 1830–1886).
The effective management of cardiac arrhythmias, either of
atrial or of ventricular origin, remains a major challenge for the
cardiologist. Sudden cardiac death most frequently due to ven-
tricular tachyarrhythmias (Hinkle and Thaler, 1982; Bayes de
Luna et al., 1989; Greene, 1990) remains the leading cause of
death in industrially developed countries, accounting for between
300,000 and 500,000 deaths each year in the United States
(Abildstrom et al., 1999; Zheng et al., 2001). In a similar manner,
atrial fibrillation is the most common rhythm disorder (Kannel
et al., 1998; Lakshminarayan et al., 2006), accounting for about
2.3 million cases in the United States and has been projected
to increase by 2.5-fold over the next half century (Anonymous,
1998). Indeed, the prevalence of this arrhythmia increases with
each decade of life (0.5% patient population between the ages of
50 and 59 years climbing to almost 9% at age 80–89 years) and
contributes to approximately one-quarter of ischemic strokes in
the elderly population (Kannel et al., 1998; Lakshminarayan et al.,
2006). The economic impact associated with the morbidity and
mortality resulting from cardiac arrhythmias is enormous [incre-
mental cost per quality-adjusted life-year as much as US $558,000
(Byrant et al., 2005)].
Despite the enormity of this problem, the development of safe
and effective anti-arrhythmic agents remains elusive. Several anti-
arrhythmic drugs have actually been shown to increase, rather
than to decrease, the risk for arrhythmic death in patients recov-
ering from myocardial infarction (Echt et al., 1991; Waldo et al.,
1996) while even “optimal” pharmacological therapy fails to sup-
press these arrhythmias completely (Buxton et al., 1999). For
example, the one-year mortality is 10% or higher, with sud-
den death accounting for approximately one-third of the deaths,
in post-myocardial infarction patients treated with β-adrenergic
receptor antagonists (Buxton et al., 1999). Implantable car-
dioverter defibrillators (ICDs) have been shown to reduce cardiac
mortality, providing a better protection from sudden death than
current pharmacological therapy in certain high-risk patient pop-
ulations (Buxton et al., 1999; Connelly et al., 2000). However,
these devices are expensive to use andmaintain (Groeneveld et al.,
2006), negatively affect the patient’s quality of life (Groeneveld
et al., 2006), have a significant risk for inappropriate shock
delivery (Poole et al., 2008), are ineffective in females patients
(Henyan et al., 2006), and, perhaps most importantly, only extend
life by a mean of 4.4 months (Connelly et al., 2000). Given
the adverse outcomes associated with ICDs and many anti-
arrhythmic medications, as well as the partial protection afforded
by even the best agents (e.g., β-adrenergic receptor antagonists
and ICDs), it is obvious that more effective anti-arrrhythmic
therapies must be developed.
The cardiovascular benefits of dietary omega-3 polyunsatu-
rated fatty acids (n-3 PUFA) have been actively investigated for
nearly 40 years. Beginning with the pioneering studies of Bang
and Dyerberg (Dyerberg et al., 1978; Bang et al., 1980), epidemi-
ological data provide strong evidence for an inverse relationship
between fatty fish consumption and cardiac mortality (Kromhout
et al., 1985; Daviglus et al., 1997). In contrast to these obser-
vational studies, interventional studies using n-3 PUFAs for the
secondary prevention of adverse cardiovascular events in patients
with heart disease have yielded conflicting results. Some stud-
ies have reported reduced sudden cardiac death or mortality
(Burr et al., 1989; Marchioli et al., 2002), while other more
recent studies have reported that n-3 PUFAs either had no effect
on cardiac arrhythmias [either ventricular arrhythmias/sudden
death (Brouwer et al., 2006; Yokoyama et al., 2007; GISSI-HF
Investigators, 2008; Kromhout et al., 2010; Rauch et al., 2010)
or atrial fibrillation (Kowey et al., 2010; Mozaffarian et al., 2012;
Sandesara et al., 2012)] or actually increased adverse cardiac
events (Burr et al., 2003; Raitt et al., 2005). Not surprisingly,
meta-analysis of these studies have yielded similar conflicting
results (Hooper et al., 2004; Jenkins et al., 2008; Brouwer et al.,
2009; Leon et al., 2009; Zhao et al., 2009; Filion et al., 2010)
with the most recent study finding that omega-3 fatty acids were
neutral, neither increasing nor decreasing the risk for arrhyth-
mias (Rizos et al., 2012). Similar conflicting results have been
obtained from animals models (McLennan et al., 1988; Billman
et al., 1994; Coronel et al., 2007; Billman et al., 2012). Of par-
ticular note, dietary n-3 PUFAs increased rather than decreased
susceptibility to arrhythmias induced by regional myocardial
ischemia in isolated hearts (Coronel et al., 2007) and pro-
voked ventricular fibrillation in conscious animals previously
shown to be at a low risk for malignant arrhythmias (Billman
et al., 2012). Despite these inconsistent findings, the American
Heart Association and the American College of Cardiology con-
tinue to recommend fish oils for the secondary prevention of
coronary artery disease (Kris-Etherton et al., 2003; Smith et al.,
2006). Based in part upon these recommendations, consumer
demand for n-3 PUFA products (both nutritional supplements
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and foods enriched with these lipids) has exploded. It has been
estimated that 5–10% of the adult US population use fish oil sup-
plements and sales are projected to exceed 7 billion dollars by the
end of 2011 [www.marketresearch.com, product reports].
Despite the intensive marketing of fish oil products, a scien-
tific consensus on the effects of n-3 PUFA on cardiac rhythm
has yet to be reached. It is the purpose of this book to stim-
ulate a discussion on the putative benefits of n-3 PUFAs on
cardiac rhythm. The book contains both state-of-the art reviews
of the literature and original research articles that address vari-
ous aspects of the effects of n-3 PUFAs on cardiac rhythm. The
book is divided into three sections. The first section addresses
the effects of n-3 PUFAs on heart rate variability (chapters
2–4). The second section provides comprehensive reviews of the
effects of n-3 PUFAs on ventricular arrhythmias/sudden death
(chapters 5–8) and on atrial fibrillation (chapters 8–10). The
third and final section (chapters 11–16) evaluates the cellular
mechanisms by which n-3 PUFAs can influence arrhythmia for-
mation. By understanding how n-3 PUFAs affect the cardiac
rhythm, the author hopes that this brief monograph will pro-
vide an education sufficient to keep at least one heart from
breaking.
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